Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease

Alain Makinson; Nicolas Martelli; Hélène Peyrière; Chrystell Turriere; Vincent Le Moing; Jacques Reynes

doi:10.1111/j.1600-0609.2007.00827.x

Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease

Eur J Haematol. 2007 Apr;78(4):358-60. doi: 10.1111/j.1600-0609.2007.00827.x.

Authors

Alain Makinson¹, Nicolas Martelli, Hélène Peyrière, Chrystell Turriere, Vincent Le Moing, Jacques Reynes

Affiliation

¹ Infectious Diseases Department, Gui de Chauliac Hospital, CHU Montpellier, France.

PMID: 17378895
DOI: 10.1111/j.1600-0609.2007.00827.x

Abstract

A HIV infected patient was treated for stage IVB Hodgkin's lymphoma by ABVD (doxorubicine, bleomycine, vinblastine, dacarbazine) chemotherapy and lopinavir-ritonavir based antiretroviral therapy inducing profound life-threatening neutropenia. Vinblastine and lopinavir-ritonavir interaction was managed with lopinavir-ritonavir interruption around chemotherapy administration, with complete remission and immunovirological success after six cycles. This unrecorded strategy is discussed.

Publication types

Case Reports

MeSH terms

Adult
Anti-HIV Agents / administration & dosage
Anti-HIV Agents / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
HIV Infections / drug therapy*
Hodgkin Disease / drug therapy*
Hodgkin Disease / virology
Humans
Male
Neutropenia / chemically induced*
Neutropenia / drug therapy
Remission Induction
Treatment Outcome
Vinblastine / administration & dosage
Vinblastine / adverse effects*

Substances

Anti-HIV Agents
Vinblastine